To ensure patients benefit from NAC aimed at breast conservation, this study developed and validated a model based on clinicopathological characteristics, traditional MRI features, and radiomics features to predict tumor shrinkage patterns after NAC in HR+/HER2- breast cancer. The gene discussed is ERBB2; the disease is neoplasm.